Jerry Katzman is the Company’s Chief Executive Officer, President, and Chairman of the Board of Directors. Dr. Katzman has always been an entrepreneur, scientist, and pioneer in medical science. His focus has targeted various biotechnology companies, biopharma, and Wall Street. Upon completion of his medical training, Dr. Katzman joined a multi-specialty group practice in Brandon, FL where he founded and established the group’s department of ophthalmology.

Ophthalmology

Herbert Gould is an ophthalmologist in Gaithersburg, Maryland and is affiliated with Adventist Healthcare Shady Grove Medical Center. He received his medical degree from NYU School of Medicine and has been in practice for more than 20 years.

Ophthalmology

Ophthalmologist specialist Anterior Segment Surgeries Specialist. Hospital Santa Lucía. Buenos Aires.

Ophthalmology

Paul H Hughes is a renowned refractive surgeon in Australia gaining his BSc and MBBS from the University of NSW in Sydney, Australia. He introduced the early refractive procedures into Australia and was one of the first ophthalmologists to have his own private refractive suites, an ophthalmic centre of excellence (Southline eye centre). He has made the journey from Refractive Keratectomy (RK) through Automated Lamellar Keratoplasy (ALK) to Photorefractive Keratectomy (PRK) then to laser in situ keratomileusis (LASIK) with the excimer laser and is now using the femtosecond laser (Visumax) to perform 3rd generation refractive surgery Small incision lenticule extraction (SMILE). Hughes has published many peer reviewed papers and spoken regularly at international ophthalmic meetings over the years. As a refractive surgeon he is very aware of the importance of Ocular Surface Disease (OSD) and its effect on excellent surgical outcomes.

Ophthalmology

Naj Sharif is a graduate of Southampton University, England (UK), where he received his BSc in Biochemistry and Physiology and his PhD in Neuroscience. He has been in the pharmaceutical industry for 31-years holding leadership positions of increasing scope and responsibility, spanning discovery research, drug development and regulatory affairs. His 22-year R&D tenure at Alcon resulted in his contributions to the discovery/development and US FDA and EMA approvals of Travatan® (Travoprost), Simbrinza®, Patanol® (Olopatadine) and Emedine® (Emedastine), to treat glaucoma/ocular hypertension and ocular allergies. He has also discovered, patented and out-licensed the first FP-prostaglandin-receptor antagonist (AL-8810) that is proving a useful pharmacological tool to dissect the role of FP-receptors in human and animal diseases.

Glaucoma treatment: Novel drugs and devices on the horizon

Aquavella was the first fellowship trained corneal surgeon in the United States when he established practice in Rochester in the mid-1960's as a specialist in cornea and external eye disease. He continues to be a leader in clinical practice, surgery, education and research.

Corneal surgeon

Ghanchi initiated his cataract surgery in 1986, refining surgical techniques to modern small incision phacoemulsification and has trained many eye surgeons.He provides patient-centred cataract surgery, usually under topical drops or local anaesthetic.

Clinical interests

She started her career as a researcher at the Institute of Neurophysiology of the CNR in Pisa directed by Prof L. Maffei, studying adult visual function. She was at University of Pennsylvania (Prof J. Sprague) and at Max-Plank Institute fur psychiatrie, Munich (prof H. Hollender). Later she became interested in the mechanism of the pre and post-natal development of the visual system. She studied the role of neurotransmitters release in collaboration with Prof L. Chalupa and environmental stress (Dr D. Protti). The main interest during the last decade is concentrated on the mechanisms involved in retinal degeneration and protection. She is enrolled in a research program in collaboration with colleagues from Università Cattolica in Rome (prof Falsini) and University of Sydney (prof J.Stone) focused on the relationship between: 1) genetic background, environmental factors and disease progression; and 2) efficacy of antioxidant/neuroprotective treatments.

Mechanisms involved in retinal degeneration and protection

Greiner, holder of three doctoral degrees, is an ophthalmologist, physician and surgeon, optometrist, teacher and medical research scientist, who has authored over 150 publications in the scientific and medical literature, and holds six U.S. patents and corresponding foreign patents in the areas of treatment of dry eyes and the integument (skin). With extensive training as both a basic and clinical scientist, many of these publications integrate both basic sciences and clinical medicine. In his 30 years of biomedical research, Dr. Greiner has presented more than 175 scientific papers at over 110 domestic and foreign meetings. Dr. Greiner is devoted to both scientific and clinical medical research as well as to clinical medicine in the fields of ophthalmology and surgery.

The development of diagnostic and therapeutic approaches for the care of patients with diseases of the ocular surface.

Professor of the Chair of Ophthalmology, Faultad de Cs. Medical National University Rosario. Chief Ophthalmology Service of the Centennial Provincial Hospital. Director of the Specialist Medical Career in Ophthalmology at the UNR. Distinguished Doctor from the city of Rosario (Deliberative Council of Rosario, 2005). Advisor to the Argentine Council of Ophthalmology. Former President Soc. Of Ophthalmology of Rosario. Evaluation partner of CONEAU, on behalf of the UNR. Professor of the Chair of Ophthalmology of the UAI.

Ophthalmology